Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	154.69	137.55	91.39	62.12	1.4	48.94
Depreciation & Amortization	29.59	28.95	27.32	25.46	24.14	20.08
Share-Based Compensation	21.49	20.24	17.86	18.69	20.5	17.3
Other Operating Activities	-7.36	-3.23	-47.39	-8.27	11.22	-44.56
Operating Cash Flow	198.41	183.5	89.18	97.99	57.27	41.76
Operating Cash Flow Growth	151.80%	105.76%	-8.99%	71.12%	37.12%	9.35%
Capital Expenditures	-37.48	-38.17	-23.61	-27.46	-33.86	-41.56
Acquisitions	-506.41	-506.41	0	0	0	0
Change in Investments	-84.43	-105.93	-7.79	1.4	-1.15	-8.82
Other Investing Activities	0.78	1.39	-1.37	-2.61	-1.41	-0.16
Investing Cash Flow	-627.55	-649.12	-32.78	-28.67	-36.42	-50.53
Share Issuance / Repurchase	-50.13	-58.14	-39.91	-28.87	-24.43	-22.29
Debt Issued / Paid	505.96	501.26	-2.19	30.36	-0.88	-3.21
Other Financing Activities	-1.77	10.97	15.66	-38.51	23.06	21.72
Financing Cash Flow	454.06	454.09	-26.44	-37.02	-2.25	-3.78
Exchange Rate Effect	-0.4	-0.28	-0.22	-0.22	0.35	-0.1
Net Cash Flow	24.53	-11.8	29.75	32.08	18.96	-12.65
Free Cash Flow	160.93	145.34	65.57	70.54	23.41	0.21
Free Cash Flow Growth	210.39%	121.66%	-7.05%	201.30%	11209.66%	-
Free Cash Flow Margin	23.80%	22.55%	13.14%	16.11%	6.69%	0.06%
Free Cash Flow Per Share	3.34	3.01	1.35	1.48	0.50	0.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).